- Previous Close
0.8000 - Open
0.8100 - Bid 0.7600 x --
- Ask 0.7900 x --
- Day's Range
0.7550 - 0.8100 - 52 Week Range
0.2350 - 2.1500 - Volume
266,254 - Avg. Volume
809,881 - Market Cap (intraday)
137.543M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
www.ltrpharma.comRecent News: LTP.AX
View MorePerformance Overview: LTP.AX
Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LTP.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LTP.AX
View MoreValuation Measures
Market Cap
137.54M
Enterprise Value
137.76M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
46.77
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-158.79%
Return on Equity (ttm)
-277.45%
Revenue (ttm)
49k
Net Income Avi to Common (ttm)
-6.95M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.1M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.83M